Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 42
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Radiology ; 296(3): 710-714, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32804600

RESUMO

HistoryAn 18-year-old man was diagnosed with precursor B-cell lymphoblastic leukemia and underwent transplantation of hematopoietic stem cells from his human leukocyte antigen-matched sister 1 year prior to admission. He was admitted to evaluate progressive shortness of breath and dry cough of 1-month duration. He did not report fever, night sweats, or hemoptysis. Physical examination revealed he was afebrile and had normal pulse oxygen saturation. The examination revealed crepitation on palpation of the anterior neck, expiratory wheezes, and crackles heard at auscultation of bases of both lungs. Extensive maculopapular rash on the skin was consistent with graft-versus-host disease (GVHD). Laboratory tests revealed elevated liver transaminase and bilirubin levels that were attributed to liver GVHD. Nonenhanced thin-section CT of the chest was performed.


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Enfisema Pulmonar , Enfisema Subcutâneo , Adolescente , Dispneia , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Enfisema Pulmonar/diagnóstico por imagem , Enfisema Pulmonar/etiologia , Enfisema Subcutâneo/diagnóstico por imagem , Enfisema Subcutâneo/etiologia , Tomografia Computadorizada por Raios X
2.
Afr J Paediatr Surg ; 21(3): 204-206, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-39162758

RESUMO

ABSTRACT: A chemoport is widely used in paediatric oncology population. Removal is a relatively easy procedure, but difficulty can be encountered in case the catheter is densely adherent to the vascular wall. It is a rare complication and is associated with long indwelling duration and acute lymphoblastic leukaemia (ALL). Forceful traction can lead to vascular injury and high morbidity. Herein, we report a 7-year-old girl with precursor B ALL who had delayed chemoport removal due to the coronavirus disease (COVID-19) pandemic. The removal process was difficult, as the catheter was adherent to the right innominate vein. Out of panic, the surgeon pulled it out forcefully. Fortunately, the catheter and its fragment were successfully retrieved completely and the child was discharged the next day. The management strategy varies and ranges from minimally invasive to open surgery. Leaving a stuck chemoport catheter in situ can be a bailout method or part of conservative management.


Assuntos
COVID-19 , Remoção de Dispositivo , Humanos , Criança , Feminino , Cateteres de Demora/efeitos adversos , SARS-CoV-2 , Cateterismo Venoso Central/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras B/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Pandemias
3.
Hematol Oncol ; 31(4): 206-12, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23616245

RESUMO

Despite improvements in treatment, the prognosis of relapsed or primary refractory acute lymphocytic leukemia (ALL) remains poor, and outcomes are worse in older adults with the short first complete remission (CR). Attainment of the second CR by salvage therapy would improve the survival of these patients and may enable them to undergo curative treatment with allogeneic hematopoietic stem cell transplantation. The fact that there are diverse salvage protocols for these adult patients but without a striking CR-induction efficacy indicates that efforts are still needed to indentify new effective reinduction regimens. In this study, the CAG regimen (cytarabine, 10 mg/m(2) subcutaneously every 12 h on days 1-14; aclarubicin, 5-7 mg/m(2) intravenously daily on days 1-8; and concurrent granulocyte colony-stimulating factor, 200 µg/m(2) /day subcutaneously) was administered to 25 patients with relapsed or refractory ALL, including 11 T-cell ALL (T-ALL) and 14 B-cell (B-ALL) patients (age range, 11-61 years; median age, 26 years), to assess its efficacy as a salvage therapy. One course of the CAG regimen resulted in an overall response [CR or partial remission (PR)] rate of 64%, a CR rate of 56% and generally mild adverse effects. An overall response was observed in all 11 T-ALL patients (10 CR and 1 PR) and 35.7% of B-ALL patients (p = 0.0009). The significant treatment potential of CAG regimen for relapsed or primary refractory ALL, especially for T-ALL patients, described in this report would prepare them for a second CR to pursue longer survival.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Terapia de Salvação , Aclarubicina/administração & dosagem , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Criança , China , Terapia Combinada , Citarabina/administração & dosagem , Intervalo Livre de Doença , Avaliação de Medicamentos , Resistencia a Medicamentos Antineoplásicos , Feminino , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Transplante de Células-Tronco Hematopoéticas , Humanos , Masculino , Pessoa de Meia-Idade , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Leucemia-Linfoma Linfoblástico de Células Precursoras/cirurgia , Recidiva , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
4.
J Pediatr Hematol Oncol ; 34(6): e246-8, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22584779

RESUMO

Necrotizing fasciitis is a potentially life-threatening infection of deep skin layers and subcutaneous tissues that can easily spread across the fascia plate and is usually the result of a combined infection with anaerobic and aerobic microorganisms. The patient typically complains of excruciating pain, which is not necessarily in accordance with clinical signs. Early recognition of the condition is very important, and aggressive treatment with a combination of antibiotics and surgical procedure is crucial. We present a case of a 15-year-old girl with acute lymphoblastic leukemia who developed necrotizing fasciitis after venous access port implantation during induction chemotherapy.


Assuntos
Cateterismo Venoso Central/efeitos adversos , Cateteres de Demora/efeitos adversos , Fasciite Necrosante/etiologia , Complicações Pós-Operatórias , Leucemia-Linfoma Linfoblástico de Células Precursoras B/complicações , Infecções por Serratia/etiologia , Serratia marcescens , Adolescente , Feminino , Humanos , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Prognóstico
5.
Transfus Apher Sci ; 45(2): 187-90, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21890415

RESUMO

Sclerodermatous chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) in children is difficult to treat and life-threatening. Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory therapy that involves the infusion of autologous peripheral blood leukocytes after ex vivo exposure to the photoactive agent 8-methoxypsoralen and ultraviolet A radiation, is an effective treatment for steroid-refractory cGVHD. After undergoing allogeneic HSCT for pre-B-cell acute lymphoblastic leukemia, a 14-year-old boy developed extensive sclerodermatous cGVHD that was refractory to prednisone, tacrolimus, and sirolimus. ECP was administered over the course of 53 months, during which the skin softened substantially and immunosuppressive therapy was discontinued. This case suggests that long-term ECP is a viable option in children with sclerodermatous cGVHD.


Assuntos
Doença Enxerto-Hospedeiro/tratamento farmacológico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Fotoferese/métodos , Escleroderma Sistêmico/tratamento farmacológico , Adolescente , Doença Crônica , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Prednisona/uso terapêutico , Transplante Homólogo , Resultado do Tratamento
6.
Arch Gynecol Obstet ; 284(5): 1289-92, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21193918

RESUMO

INTRODUCTION: Primary lymphomas of the female genital tract are rare. Most involve the cervix rather than the uterine corpus. Many cases of primary endometrial lymphoma are diagnosed as diffuse large B cell type, whereas the precursor B cell lymphoblastic type is extremely rare. MATERIALS AND METHODS: We report a case of precursor B cell lymphoblastic lymphoma of uterine corpus which was successfully treated with surgery and chemotherapy. Staging evaluation revealed tumor limited to the uterine corpus (stage I(E)). After receiving a total abdominal hysterectomy, bilateral salpingooophorectomy, lymph node dissection and combination chemotherapy, the patient is currently free of disease after follow-up of 42 months. CONCLUSION: If correct diagnosis is established and appropriate therapy is chosen, the prognosis of precursor B-LBL of uterine corpus is expected to be good. The literature on primary precursor B cell lymphoblastic lymphoma of the uterine corpus is reviewed.


Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras B/terapia , Neoplasias Uterinas/terapia , Adulto , Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica , Terapia Combinada , Feminino , Humanos , Histerectomia/métodos , Excisão de Linfonodo , Ovariectomia/métodos , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Neoplasias Uterinas/tratamento farmacológico , Neoplasias Uterinas/patologia , Neoplasias Uterinas/cirurgia
7.
Artigo em Espanhol | MEDLINE | ID: mdl-22011663

RESUMO

26 year-old male patient with diagnosis of acute lymphoblastic leukemia in 2006, who underwent chemotherapy and suffered a relapse and pulmonary aspergillosis as a complication. In 2009, he received bone marrow transplant. After it, he developed cutaneous and intestinal graft versus host disease (GVH). He was admitted for diarrhea. Then he presented grade IV dyspnea, patchy alveolar infiltrates on chest computed tomography and pancytopenia with impaired renal function as laboratory findings. He entered Intensive Care Unit, dying 7 days later. The oncologist who discussed the case defined this patient as a high risk case because of type of transplant received, relapse and complications. His diagnostic hypotheses were: CMV infection, pulmonary aspergillosis reactivation, chronic GVH, Pneumocystis jiroveci infection, mycobacteriosis and pseudomembranous colitis. Partial autopsy revealed diffuse intra-alveolar hemorrhage, diffuse alveolar damage, right pulmonary infarction with microthrombosis and bronchiolitis obliterans organizing pneumonia.


Assuntos
Transplante de Medula Óssea/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Adulto , Autopsia , Evolução Fatal , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patologia
8.
Am J Hematol ; 84(4): 228-30, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19260120

RESUMO

The standard dose of clofarabine is 52 mg/m2 for pediatrics and 40 mg/m2 in adults. Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo-HSCT. All patients had a significant response to therapy. Published pharmacokinetic analysis revealed no difference in peak plasma or intracellular concentrations at clofarabine dosed above 40 mg/m2, yet inhibition of replication in leukemia cells was only sustained over 24 hr at 55 mg/m2. Despite this, there have been no reports of high dose clofarabine used in this setting. Our experience implies that there may be a niche role for clofarabine in reducing disease burden before allo-HSCT for adults with relapsed ALL.


Assuntos
Nucleotídeos de Adenina/uso terapêutico , Antimetabólitos Antineoplásicos/uso terapêutico , Arabinonucleosídeos/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células T Precursoras/tratamento farmacológico , Terapia de Salvação , Nucleotídeos de Adenina/administração & dosagem , Nucleotídeos de Adenina/efeitos adversos , Adulto , Antimetabólitos Antineoplásicos/administração & dosagem , Antimetabólitos Antineoplásicos/efeitos adversos , Antimetabólitos Antineoplásicos/sangue , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Arabinonucleosídeos/administração & dosagem , Arabinonucleosídeos/efeitos adversos , Ensaios Clínicos como Assunto/estatística & dados numéricos , Clofarabina , Terapia Combinada , Ciclofosfamida/administração & dosagem , Citarabina/administração & dosagem , Dexametasona/administração & dosagem , Relação Dose-Resposta a Droga , Doxorrubicina/administração & dosagem , Avaliação de Medicamentos , Etoposídeo/administração & dosagem , Evolução Fatal , Filgrastim , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Transplante de Células-Tronco Hematopoéticas , Humanos , Idarubicina/administração & dosagem , Masculino , Mitoxantrona/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Leucemia-Linfoma Linfoblástico de Células T Precursoras/cirurgia , Proteínas Recombinantes , Recidiva , Indução de Remissão , Reoperação , Vidarabina/administração & dosagem , Vidarabina/análogos & derivados , Vincristina/administração & dosagem , Adulto Jovem
9.
Biol Blood Marrow Transplant ; 14(6): 622-30, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18489987

RESUMO

INK4A/ARF mutations are acquired in bcr/abl(+) lymphoid blast phase chronic myelogenous leukemia (CML) and bcr/abl(+) acute lymphoblastic leukemia (ALL). Donor lymphocyte infusion and graft-versus-leukemia (GVL) are generally ineffective in such ALLs, whereas GVL is highly active against bcr/abl(+) CML, which does not have a lesion in the INK4A/ARF locus. The mechanisms for the ineffectiveness of GVL are not fully known, and it is possible that intrinsic resistance of acute lymphoid leukemias to immune effectors associated with allogeneic GVL may contribute to ineffectiveness. This work tested the hypothesis that INK4A/ARF mutations that are associated with transformation of bcr/abl(+) CML to an ALL phenotype, and that are associated with increased resistance to apoptosis render ALL cells insensitive to allogeneic immune responses to minor histocompatibility antigens (mHA). Murine acute pre-B ALLs were induced by transfer of the human p210 bcr/abl gene into bone marrow of INK4A/ARF null mice. These ALL lines were then studied in a murine model of MHC-matched, mHA-mismatched allogeneic BMT. In vivo growth of these ALLs was inhibited in allogeneic transplants characterized by active allogeneic immune responses compared to their behavior in syngeneic transplants. In vitro ALLs with INK4A/ARF, p210 bcr/abl, or p190 bcr/abl mutations remained sensitive to anti-mHA cytolytic T cells. In addition, the ALLs were capable of inducing primary immune responses to mHAs in vivo. Thus, ALLs with INK4A/ARF or bcr/abl mutations are not intrinsically resistant to allogeneic T cell responses, suggesting that active immunotherapies against mHA have the potential to control such acute lymphoblastic leukemias.


Assuntos
Inibidor p16 de Quinase Dependente de Ciclina/genética , Proteínas de Fusão bcr-abl/genética , Efeito Enxerto vs Leucemia/imunologia , Antígenos de Histocompatibilidade Menor/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/imunologia , Subpopulações de Linfócitos T/imunologia , Linfócitos T Citotóxicos/imunologia , Animais , Apoptose/imunologia , Transplante de Medula Óssea , Células Cultivadas/imunologia , Inibidor p16 de Quinase Dependente de Ciclina/deficiência , Progressão da Doença , Genes abl , Genes p16 , Humanos , Células Matadoras Naturais/imunologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Modelos Imunológicos , Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Quimera por Radiação , Subpopulações de Linfócitos T/transplante , Linfócitos T Citotóxicos/transplante , Transplante Homólogo/imunologia
10.
World Neurosurg ; 109: 117-118, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28962960

RESUMO

Acute lymphoblastic lymphoma is a malignant hematologic disease in childhood but rarely initially involves epidural compartment in adults. A 20-year-old male presented with progressive osphyalgia with constipation. Contrasted magnetic resonance imaging showed multiple vertebrae of hypointense T1 signals and an intraspinal epidural lesion. Subtotal resection was achieved. Histopathology suggested malignant B-cell lymphoma with Ki-67 of 90% and positivity of leukocyte common antigen. A bone marrow biopsy was unequivocally diagnostic of B-cell acute lymphoblastic lymphoma followed by chemotherapy (methotrexate) and partial recovery was observed. The marrow biopsy was necessary if without hypercalcemia and abnormal peripheral blood examination.


Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Neoplasias da Coluna Vertebral/cirurgia , Coluna Vertebral/cirurgia , Antimetabólitos Antineoplásicos/uso terapêutico , Terapia Combinada , Humanos , Imageamento por Ressonância Magnética , Masculino , Metotrexato/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/diagnóstico por imagem , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Neoplasias da Coluna Vertebral/diagnóstico por imagem , Neoplasias da Coluna Vertebral/tratamento farmacológico , Coluna Vertebral/diagnóstico por imagem , Adulto Jovem
11.
Haematologica ; 92(5): 612-8, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17488684

RESUMO

BACKGROUND AND OBJECTIVES: The molecular analysis of minimal residual disease (MRD) may provide information on the risk of recurrence in patients with acute lymphoblastic leukemia (ALL). The aim of this study was to correlate the kinetics of MRD clearance after allogeneic transplantation with the clinical outcome of adults with ALL. DESIGN AND METHODS: MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) using probes derived from fusion chimeric genes (BCR/ABL and MLL/AF4) (n=22) or rearrangements of the T-cell receptor or immunoglobulin genes (n=21). Forty-three adult patients with ALL were studied to correlate the kinetics of MRD clearance before and after allogeneic hematopoietic stem cell transplantation. RESULTS: At 36 months, the overall survival of patients who underwent transplantation in hematologic remission (n= 37) was 80% for those who were PCR-negative before transplantation (n= 12) compared to 49% for PCR-positive patients (n= 25)(p=0.17). For the same patients the cumulative incidence of relapse was 0% and 46%, respectively (p=0.027). Moreover, the relapse rate of patients who were PCR-negative at day +100 after transplantation was remarkably low (7%) compared to that among patients who were PCR-positive (80%, p=0.0006). INTERPRETATION AND CONCLUSIONS: The kinetics of MRD clearance may help to identify patients at high risk of leukemia relapse after allogeneic stem cell transplantation. Patients not achieving an early molecular remission after transplantation require prompt and appropriate pre-emptive treatments such as infusions of donor lymphocytes or new experimental drugs.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Transplante Homólogo , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética , Benzamidas , Biomarcadores Tumorais/sangue , Ensaios Clínicos como Assunto/estatística & dados numéricos , Estudos de Coortes , Terapia Combinada , Feminino , Proteínas de Fusão bcr-abl/sangue , Deleção de Genes , Rearranjo Gênico do Linfócito B , Rearranjo Gênico do Linfócito T , Humanos , Mesilato de Imatinib , Estimativa de Kaplan-Meier , Cinética , Leucemia-Linfoma de Células T do Adulto/sangue , Leucemia-Linfoma de Células T do Adulto/tratamento farmacológico , Leucemia-Linfoma de Células T do Adulto/genética , Leucemia-Linfoma de Células T do Adulto/mortalidade , Leucemia-Linfoma de Células T do Adulto/patologia , Leucemia-Linfoma de Células T do Adulto/cirurgia , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Proteína de Leucina Linfoide-Mieloide/sangue , Neoplasia Residual , Proteínas de Fusão Oncogênica/sangue , Piperazinas/administração & dosagem , Reação em Cadeia da Polimerase , Leucemia-Linfoma Linfoblástico de Células Precursoras B/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras/cirurgia , Proteínas Proto-Oncogênicas/genética , Pirimidinas/administração & dosagem , Indução de Remissão , Risco , Análise de Sobrevida , Taxa de Sobrevida , Proteína 1 de Leucemia Linfocítica Aguda de Células T
13.
Haematologica ; 91(5 Suppl): ECR07, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16709515

RESUMO

Isolated renal relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) in children with acute lymphoblastic leukemia (ALL) is a rare condition. Generally, in ALL, the sites most frequently affected by extramedullary relapse are the central nervous system (CNS) and the testicles. Here we report on three young boys with relapsed B-precursor ALL, who underwent alloHSCT from HLA-identical siblings and suffered a histopathologically proven isolated unilateral renal relapse (two patients) or a combined renal and testicular relapse (one patient) 6, 10 and 12 months post alloHSCT. In all patients at the time of relapse bone marrow showed complete remission with complete donor hematopoiesis. They all received total body irradiation with partial shielding of the kidneys as part of their conditioning therapy, such that renal shielding could be an explanation for the observed accumulation of renal relapses. Moreover, during the past few years so called immune privilege has been postulated for frequent relapse sites such as the CNS, the testicles and the anterior chamber of the eye. Impaired accessability of these organs by cytotoxic T-cells (CTLs) with a reduced graft-versus-leukemia (GvL) effect after alloHSCT is based on a number of different molecular and cellular mechanisms. Similar mechanisms have been shown to be effective in the tubulointerstitial space of the kidney, rendering the kidney a potentially immune privileged site. Due to these observations we advocate sufficient treatment of the kidneys during conditioning therapy.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Rim/patologia , Infiltração Leucêmica , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Criança , Pré-Escolar , Terapia Combinada , Células Dendríticas/transplante , Progressão da Doença , Etoposídeo/uso terapêutico , Evolução Fatal , Humanos , Imunoterapia , Rim/efeitos da radiação , Transfusão de Leucócitos , Imageamento por Ressonância Magnética , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/radioterapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/cirurgia , Proteção Radiológica , Recidiva , Terapia de Salvação , Tomografia Computadorizada por Raios X , Condicionamento Pré-Transplante/efeitos adversos , Transplante Homólogo , Irradiação Corporal Total/efeitos adversos
14.
Haematologica ; 91(5 Suppl): ECR09, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16709517

RESUMO

An 18-month-old girl was diagnosed with pre-pre-B ALL/t(4;11) leukemia, which during the treatment and after matched bone marrow transplantation (BMT), underwent two consecutive switches from lymphoid to myeloid lineage and vice versa. The high expression of HOXA9 and FLT3 genes remaining genotypically stable in a leukemia throughout phenotypic switches, suggests that this leukemia may have originated as a common B/myeloid progenitors.


Assuntos
Antígenos CD/análise , Antígenos de Neoplasias/análise , Linfócitos B/patologia , Rearranjo Gênico , Imunofenotipagem , Proteína de Leucina Linfoide-Mieloide/genética , Proteínas de Fusão Oncogênica/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfócitos B/imunologia , Linhagem da Célula , Cromossomos Humanos Par 11/genética , Cromossomos Humanos Par 11/ultraestrutura , Cromossomos Humanos Par 4/genética , Cromossomos Humanos Par 4/ultraestrutura , Células Clonais/patologia , Terapia Combinada , Evolução Fatal , Feminino , Regulação Leucêmica da Expressão Gênica , Rearranjo Gênico do Linfócito B , Genes de Imunoglobulinas , Células-Tronco Hematopoéticas/imunologia , Células-Tronco Hematopoéticas/patologia , Histona-Lisina N-Metiltransferase , Proteínas de Homeodomínio/genética , Humanos , Lactente , Modelos Biológicos , Proteínas de Neoplasias/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Recidiva , Translocação Genética , Tirosina Quinase 3 Semelhante a fms/genética
15.
BMJ Case Rep ; 20162016 Nov 29.
Artigo em Inglês | MEDLINE | ID: mdl-27899386

RESUMO

Thyroid abscess is a very rare clinical condition. It usually occurs in immunocompromised individuals or those with underlying malignancy. We report a case of multiple thyroid abscesses in the patient with Pre B acute lymphoblastic leukaemia which developed secondary to hematogenous spread from pyomyositis of right calf muscle. The patient developed sepsis-associated disseminated intravascular coagulation, which got resolved after thyroidectomy. He became afebrile after surgical intervention. Unfortunately, all the cultures were negative. Since there are few case series and reports, there are no clear guidelines for management of thyroid abscess. We conclude that though rare, thyroid abscess may be the cause of persistent fever in immunocompromised patients.


Assuntos
Abscesso/patologia , Antibacterianos/uso terapêutico , Drenagem , Febre/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patologia , Piomiosite/diagnóstico , Sepse/diagnóstico , Doenças da Glândula Tireoide/patologia , Glândula Tireoide/patologia , Tireoidectomia , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica , Clindamicina/uso terapêutico , Febre/etiologia , Febre/patologia , Humanos , Masculino , Meropeném , Leucemia-Linfoma Linfoblástico de Células Precursoras B/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Prednisolona/uso terapêutico , Piomiosite/complicações , Piomiosite/tratamento farmacológico , Sepse/tratamento farmacológico , Sepse/etiologia , Teicoplanina/uso terapêutico , Tienamicinas/uso terapêutico , Doenças da Glândula Tireoide/etiologia , Doenças da Glândula Tireoide/cirurgia , Resultado do Tratamento
16.
Haematologica ; 90 Suppl: ECR31, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16266922

RESUMO

Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT), but membranous glomerulopathy (MG) has rarely been described as a manifestation of chronic GVHD. We report two cases of MG in children who underwent allogeneic HSCT. The clinical findings were characterized by edema of the lower extremities and nephrotic proteinuria in one case and hypertension, hematuria and edema with non-nephrotic proteinuria in the other one. Renal biopsy was consistent with MG and appropriate immunosuppressive therapy was prescribed. Both patients achieved complete remission and are alive without renal disease 4 and 2 years after the diagnosis of MG. The normal levels of albumin and non-nephrotic proteinuria in one of the two cases raise the question of whether the real incidence of MG after HSCT is underestimated. Therefore, we strongly suggest regular urine analysis during the follow-up of children undergoing HSCT in order to diagnose MG early.


Assuntos
Anemia Refratária com Excesso de Blastos/cirurgia , Glomerulonefrite Membranosa/etiologia , Doença Enxerto-Hospedeiro/complicações , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Transplante Homólogo/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Asparaginase/administração & dosagem , Criança , Pré-Escolar , Terapia Combinada , Ciclofosfamida/administração & dosagem , Citarabina/administração & dosagem , Daunorrubicina/administração & dosagem , Edema/etiologia , Glomerulonefrite Membranosa/diagnóstico , Glomerulonefrite Membranosa/tratamento farmacológico , Doença Enxerto-Hospedeiro/tratamento farmacológico , Hepatopatia Veno-Oclusiva/etiologia , Humanos , Imunossupressores/uso terapêutico , Masculino , Mercaptopurina/administração & dosagem , Metotrexato/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Prednisona/administração & dosagem , Indução de Remissão , Condicionamento Pré-Transplante , Vincristina/administração & dosagem
17.
Haematologica ; 90(12): 1701-3, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16330449

RESUMO

In a retrospective analysis of 24 children with refractory or multiply relapsed acute lymphoblastic leukemia (ALL), a salvage regimen comprising amsacrine, etoposide, and high-dose methylprednisolone AEP achieved a significant treatment response in 11 of 19 evaluable patients (8 complete and 3 partial remissions). Five of 9 AEP-responsive patients who underwent subsequent stem cell transplantation are alive (median follow-up: 43 months; range 10 to 91). The load of minimal residual disease prior to transplantation appears to be predictive for outcome in this very poor-prognosis subgroup of ALL.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Terapia de Salvação , Adolescente , Amsacrina/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Criança , Pré-Escolar , Terapia Combinada , Citarabina/administração & dosagem , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Dexametasona/administração & dosagem , Avaliação de Medicamentos , Sinergismo Farmacológico , Etoposídeo/administração & dosagem , Feminino , Filgrastim , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Humanos , Idarubicina/administração & dosagem , Lactente , Leucemia-Linfoma de Células T do Adulto/tratamento farmacológico , Leucemia-Linfoma de Células T do Adulto/cirurgia , Masculino , Metilprednisolona/administração & dosagem , Neoplasia Residual , Transplante de Células-Tronco de Sangue Periférico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/cirurgia , Prognóstico , Proteínas Recombinantes , Indução de Remissão , Estudos Retrospectivos , Análise de Sobrevida , Tiotepa/administração & dosagem , Topotecan/administração & dosagem , Resultado do Tratamento , Vidarabina/administração & dosagem , Vidarabina/análogos & derivados , Vimblastina/administração & dosagem , Vimblastina/análogos & derivados
18.
Bone Marrow Transplant ; 4(5): 587-9, 1989 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-2551437

RESUMO

Cytomegalovirus (CMV) infection of the retina is a well recognized complication in patients with the acquired immune deficiency syndrome but is rarely seen after bone marrow transplantation (BMT). Among a variety of drugs ganciclovir so far appears to be the most effective therapy for CMV retinitis, but in previous studies relapses occurred in all patients in whom ganciclovir was interrupted. We report the clinical findings in a 22-year-old BMT recipient who developed bilateral exudative CMV retinitis 64 days after BMT despite prophylactic treatment with high-titer CMV-immunoglobulins and transfusions of CMV-negative blood products and donor bone marrow. During a 12 day course of treatment with 7.5 mg/kg/day of ganciclovir the CMV retinitis improved and viruria ceased on day 4 of therapy. In contrast to the previous reports, CMV retinitis in this patient continued to improve even after ganciclovir was stopped and eventually complete healing of all intraretinal lesions as well as total reconstitution of the visual acuity was achieved. He is now free of disease and without relapse of CMV retinitis more than 1 year after transplantation.


Assuntos
Transplante de Medula Óssea/efeitos adversos , Infecções por Citomegalovirus/tratamento farmacológico , Ganciclovir/uso terapêutico , Retinite/tratamento farmacológico , Adulto , Anticorpos Antivirais/análise , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Transplante de Medula Óssea/imunologia , Citomegalovirus/imunologia , Infecções por Citomegalovirus/etiologia , Ganciclovir/administração & dosagem , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Retinite/etiologia
19.
Bone Marrow Transplant ; 11(2): 169-73, 1993 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8435666

RESUMO

We report the successful purging of leukemia cells bearing the Philadelphia chromosome and BCR/ABL transcripts by long-term marrow culture (LTC), and subsequent grafting of the purged marrow in a case of refractory acute lymphoblastic leukemia. The efficiency of the purge was evaluated by polymerase chain reaction (PCR) for BCR/ABL transcripts. In two LTCs initiated in the blastic stage, we demonstrated the selective effect of three culture media (serum dependent, serum-free (SF) supplemented or not with IL3 and GM-CSF) on the proliferative potential of normal hematopoietic (CFU-GM/BFU-E) and leukemic progenitors (CFU-ALL). BCR/ABL positive cells disappeared after 3 to 4 weeks of culture. The addition of IL3 and GM-CSF to the SF medium enhanced the growth of CFU-GM/BFU-E and shortened the purging period. We therefore carried out a LTC in the presence of IL3 and GM-CSF with marrow harvested in morphological remission. BCR/ABL positivity was detected at the outset, although no leukemia cells could be identified. The BCR/ABL was no longer found by PCR in the 7 and 14 day LTCs. The patient, consolidated by high dose polychemotherapy and total body irradiation, was infused with the 14 day LTC. This study indicates that PCR is a useful and sensitive technique for monitoring tumor cell reduction after LTC prior to autografting.


Assuntos
Purging da Medula Óssea , Proteínas de Fusão bcr-abl/análise , Proteínas de Neoplasias/análise , Células-Tronco Neoplásicas/química , Reação em Cadeia da Polimerase , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Transplante de Medula Óssea , Meios de Cultura Livres de Soro , Proteínas de Fusão bcr-abl/genética , Proteínas de Neoplasias/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patologia , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/cirurgia , Transplante Autólogo
20.
Bone Marrow Transplant ; 6(6): 399-403, 1990 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-2097008

RESUMO

Engraftment following allogeneic bone marrow transplantation (BMT) was assessed in three cases, two of which were sex-mismatched and one sex-matched. The polymerase chain reaction (PCR) was used to amplify the hypervariable region lying 3' to the apolipoprotein B gene on chromosome 2. Amplification of this region provided informative marker bands capable of distinguishing host/donor populations in each case. The method allowed rapid analysis of minimal numbers of cells from peripheral blood and bone marrow in the early stages following BMT and was predictive of either successful engraftment or graft failure.


Assuntos
Transplante de Medula Óssea/patologia , Sobrevivência de Enxerto , Reação em Cadeia da Polimerase , Adulto , Anemia Aplástica/cirurgia , Criança , Quimera , DNA/análise , Feminino , Marcadores Genéticos , Sobrevivência de Enxerto/genética , Células-Tronco Hematopoéticas/química , Humanos , Região Variável de Imunoglobulina/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/cirurgia , Contagem de Leucócitos , Leucócitos/química , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras B/cirurgia , Doadores de Tecidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA